Phosphagenics seeks listing on UK's AIM
Wednesday, 26 May, 2004
Melbourne-based Phosphagenics (ASX:POH) -– formerly Vital Capital -– has flagged its intention to seek a dual listing on the London Stock Exchange's Alternative Investment Market (AIM).
The company said in a statement that it believes the listing will provide access to a more developed capital market for the company’s globally orientated healthcare products
Investment bank Williams de Broë has been appointed as nominated adviser and stockbroker for the dual listing process.
Phosphagenics last month announced the successful completion of animal studies for its transdermal delivery system for morphine. The system uses d-alpha tocopherol combined with a phosophate molecule to create an enhanced form of Vitamin E which carries morphine across the dermis.
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
